Oncopharmpod
Glofitamab & TALAPRO - 2
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:12:59
- Mas informaciones
Informações:
Sinopsis
This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
